Tirzepatide mitigates atherosclerosis progression and modulates oxLDL-mediated proatherogenic effects in macrophages: evidence for M1/M2 homeostasis restoration.
Tirzepatide isn’t just stirring up interest in metabolic research — it’s now flexing its muscle in atherosclerosis studies. Researchers from Shenyang Medical College put tirzepatide, a dual GLP-1/GIP receptor agonist, to the test in a classic mouse model (apoE-/-) and in cultured macrophages. The results: less plaque, better lipid numbers, and a shift in macrophage behavior that could matter for anyone studying cardiovascular risk.
Arch Pharm Res
by Kang M, Ren H, Zhen Y et al.
“Tirzepatide mitigates atherosclerosis progression and modulates oxLDL-mediated proatherogenic effects in macrophages: evidence for M1/M2 homeostasis restoration. Kang M(#)(1), Ren H(#)(2), Zhen Y(#)(1), Liu L(3), Xu Q(1), Ma Y(1), Zhang L(1), Jia H(4), Chen Q(5), Jiang Y(6), Gao J(7), Liu Y(8), Zhou MS(9). Author information: (1)Shenyang Key Laboratory of Vascular Biology Institute, Science and Experimental Research Center, Shenyang Medical College, Huanghe N St. 146, Shenyang, 110034, China. (2)Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 21000, China. (3)Department of Cardiology, The 2nd Affiliated Hospital of Shenyang Medical College, Shenyang, 110002, China. (4)School of Traditional Chinese Medicine, Shenyang Medical College, Shenyang, 110034, China. (5)School of Pharmacy, Shenyang Medical College, Shenyang, 110034, China. (6)School of the First Clinical Medicine, Shenyang Medical College, Shenyang, 110034, China. (7)Department of Cardiology, The 2nd Affiliated Hospital of Shenyang Medical College, Shenyang, 110002, China. 48026486@qq.com. (8)Shenyang Key Laboratory of Vascular Biology Institute, Science and Experimental Research Center, Shenyang Medical College, Huanghe N St. 146, Shenyang, 110034, China. yueyangliu1989@163.com. (9)Shenyang Key Laboratory of Vascular Biology Institute, Science and Experimental Research Center, Shenyang Medical College, Huanghe N St. 146, Shenyang, 110034, China. zhoums1963@163.com. (#)Contributed equally Tirzepatide (TZP), a novel dual agonist of glucagon-like peptide (GLP)-1/glucose-dependent insulinotropic polypeptide (GIP) receptors (GLP-1R/GIPR), has been shown to reduce cardiovascular (CV) risk in patients with diabetes or obesity. This study investigated anti-atherosclerotic effects of TZP and the underlying mechanisms using apo E-/- mice and cultured macrophages. In the present study, apo E-/- mice were fed a high fat/high cholesterol (HF) diet with or without TZP treatment for 12 weeks. Atherosclerotic lesions, metabolic parameters, and M1/M2 macrophage homeostasis were assessed. In vitro, RAW264.7 and THP-1 macrophages were treated with oxLDL and TZP to evaluate foam cell formation, inflammation, and signaling pathways. The results showed that TZP significantly lowered body weight, plasma lipids, and atherosclerotic burden in vivo, and favorably modulated the expression of M1/M2 macrophage markers. ANCOVA suggested that the anti-atherosclerotic effect may be partially independent of metabolic improvements, although further studies are needed for confirmation. While these data support macrophage modulation as a key mechanism, other vascular cell types and plaque components likely contribute to the observed plaque-stabilizing effects. In vitro, TZP inhibited oxidized Low-density Lipoprotein (oxLDL)-induced cholesterol accumulation and foam cell formation, cluster of differentiation (CD) 36 expression and M1 inflammatory markers while promoting M2 markers. These effects were blocked by combined GLP-1R/GIPR antagonism and further confirmed in human THP-1 macrophages. Mechanistically, the anti-inflammatory effects and modulation of M1/M2 macrophage homeostasis by TZP were mediated via activating kruppel-like factor 4/the peroxisome proliferator-activated receptor γ pathway. Collectively, these findings indicate that TZP confers CV protection and anti-atherosclerotic benefits through both lipid-lowering dependent and independent mechanisms, highlighting its therapeutic potential for diabetic and obese patients who are at high risk of atherosclerotic CV diseases. © 2026. The Pharmaceutical Society of Korea. Conflict of interest statement: Declarations. Conflict of interest: All authors declare that the work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”
Key takeaway: Tirzepatide didn’t just help with body weight and plasma lipids. It also cut down atherosclerotic burden, showing potential for both metabolic and direct vascular benefits.
Here’s what stands out:
In high-fat diet mice, tirzepatide reduced body weight, plasma cholesterol, and the size of atherosclerotic lesions
The peptide shifted macrophage polarization from M1 (pro-inflammatory) to M2 (anti-inflammatory), restoring homeostasis
In cell cultures, tirzepatide blocked oxLDL-driven cholesterol buildup and foam cell formation — a key early event in plaque development
These effects were tied to the KLF4/PPARγ signaling pathway, and blocked by GLP-1R/GIPR antagonists, confirming receptor involvement
The anti-atherogenic impact wasn’t just about lowering lipids; macrophage modulation played a big role
The research team suggests tirzepatide’s atherosclerosis effects aren’t simply downstream of its metabolic perks. There’s a case to be made for direct immunomodulation and plaque stabilization via macrophage phenotype control.
For researchers, tirzepatide is looking like a versatile compound — not just for diabetes or obesity models, but as a tool for dissecting inflammation and plaque biology. The field just got another reason to keep an eye on this peptide.
Related Reading
Reply: Semaglutide in Frail HFpEF: Need for Objective Functional Measures and Body Composition Assessment.
News · JACC Heart FailSemaglutide in Frail HFpEF: Need for Objective Functional Measures and Body Composition Assessment.
News · NeuropsychopharmacologyIdentification of an intrusive-hypervigilant phenotype of posttraumatic stress symptoms with unique stress peptide and amygdala functional connectivity profiles.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.